Page values for "Lithium"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Lithium
brand	`String`	Lithobid (extended-release); Eskalith (discontinued in US); Carbolith (Canada); Priadel (UK); Camcolit (UK)
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Mood stabilizers\|Mood stabilizer]] • [[:Category:Antimanic medicines\|Antimanic]]
mechanism	`String`
uses	`String`
starting_dose	`String`
preparations	`String`	Lithium carbonate: immediate-release capsules (150 mg, 300 mg, 600 mg) and tablets (300 mg); extended-release tablets (300 mg, 450 mg). Lithium citrate: oral solution (8 mEq/5 mL, equivalent to 300 mg lithium carbonate per 5 mL) for patients unable to swallow tablets.
fda_max	`String`	No defined absolute maximum; dosing is guided by serum level monitoring. Levels above 1.5 mEq/L carry increasing toxicity risk. Levels consistently above 1.2 mEq/L are generally not maintained in clinical practice.'"`UNIQ--ref-00000052-QINU`"'
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Antimanic effects begin within 5-7 days of reaching therapeutic serum levels, with full response often requiring 2-3 weeks. For acute mania, a neuroleptic is typically added for rapid sedation while lithium takes effect.'"`UNIQ--ref-00000053-QINU`"'
duration	`String`
halflife	`String`	Approximately 18-24 hours after acute administration; may extend to 36-48 hours with chronic dosing as tissue compartments equilibrate. Serum trough levels should be drawn 12 hours after the last dose for accurate interpretation.'"`UNIQ--ref-00000055-QINU`"'
bioavailability	`String`
pregnancy	`String`
legal	`String`	Not a controlled substance in the United States, European Union, United Kingdom, Canada, or Australia. Prescription-only in all of these jurisdictions due to the narrow therapeutic index and the need for serum monitoring. No abuse potential has been identified.